readthroughSign in
Nov 12, 2026Trial update

Takeda's Phase 3 zasocitinib trial in biologic-naive PsA patients updates as not recruiting

The LATITUDE-PsA-3001 study, testing TAK-279 against placebo and an active comparator, shows updated status with enrollment at 1583 participants.

One Takeda registry update is in focus this week.

  • Takeda's Phase 3 trial of zasocitinib (TAK-279) in biologic-naive psoriatic arthritis patients, "LATITUDE-PsA-3001," is listed as active not recruiting as of the November 12, 2026 update. The study is a multi-center, randomized, double-blind, placebo- and active-controlled Phase 3 trial evaluating zasocitinib in subjects with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs.1 Enrollment reached 1583 participants, with the trial assigning patients to zasocitinib Dose A, Dose B, an active comparator, or a placebo arm that later switches to zasocitinib.1 The primary outcome measures the percentage of participants achieving American College of Rheumatology 20 (ACR20) response at Week 16 for zasocitinib Dose A and B compared to placebo.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.